Back to library
ImmuneSubcutaneous
LL-37
Also known as: Cathelicidin · Human cationic antimicrobial protein 18 · hCAP18
37-amino-acid cathelicidin antimicrobial peptide. Disrupts microbial membranes, neutralizes LPS, modulates innate immune cell recruitment, and exhibits direct antiviral activity against enveloped viruses.
At a glance
- Half-life
- 1 hours
- Common route
- Subcutaneous
- Typical dose range
- 100–1,000mcg
- Stability (reconstituted)
- 14days refrigerated
Best timing
Cycled — 5–10 day courses common for chronic infection protocols. Daily dosing during acute use.
Contraindications
- Pregnancy
- Active autoimmune disease (LL-37 is implicated in some autoimmune pathology — psoriasis, lupus)
- Limited human safety data outside experimental settings
Watch symptoms
- Injection site irritation (can be significant — LL-37 is membrane-active)
- Histamine-like flushing
- Headache
- Possible autoimmune symptom flare
- Mast cell activation in sensitive individuals
Citations